| abstract |
Quinazoline derivative of the formula 1 wherein X1 is a direct link or a group such as CO, C(R2)2 and CH(OR2); Q1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1 optionally bears up to 3 substituents; m is 1 or 2; each R1 may be a group such as hydrogen, halogen and trifluoromethyl; Q2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2 optionally bears up to 3 substituents; or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer. |